Nike Inc vs Nuwellis Inc — how do they compare? Nike Inc trades at $42.97 (market cap $64.49B), while Nuwellis Inc trades at $2.94 (market cap $1.09M). The key difference: Nike Inc is far larger — about 59165.1× Nuwellis Inc's market cap, and Nike Inc pays a 3.77% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NKE | NUWE | |
|---|---|---|
Market Cap | $64.49B | $1.09M |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $79.24 | $527.46 |
52-Week Low | $40.75 | $2.80 |
Enterprise Value | $66.49B | -$722.58K |
Dividend Yield | 3.77% | — |
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $43.76, down 1.82% on the day, with a neutral technical signal and bullish moving averages. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.72 surpassing the $0.11 estimate. Revenue declined to $46.31B in 2025, while net income margin compressed to 6.7%. The stock holds a consensus analyst price target of $50.80, with 49% of analysts rating it a Buy. A dividend of $0.41 is scheduled for payment on July 1, 2026.
Nike's outlook is mixed: strong brand equity and earnings beats support upside potential, but revenue pressures and margin compression pose risks. Investors face trade-offs between valuation support and execution challenges in key markets like China. The stock's current discount to consensus target suggests cautious optimism amid turnaround efforts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →